跳到正文
原文
MedPage Today·· 10 天前AI 评分35

建立独立疫苗安全机构以增强公众信任

Could an Independent Agency for Vaccine Safety Strengthen Public Trust?

AI 导读

Daniel Salmon博士提议建立一个类似于美国国家运输安全委员会的全国疫苗安全委员会,以进行独立的快速调查,增强公众对疫苗安全的信任。该委员会将整合现有数据和专业知识,确保调查的独立性和可信度。

正文

— Daniel Salmon proposes something modeled on the National Transportation Safety Board

by Gregory Laub, Senior Director, Video, MedPage Today; Kristina Fiore, Director of Enterprise & Investigative Reporting, MedPage Today

November 10, 2026 • 4 min read

Routinely used vaccines in the U.S. are very safe, but questions about potential adverse events still require thorough, credible investigations. Daniel Salmon, PhD, MPH, of the Johns Hopkins Bloomberg School of Public Health in Baltimore, argues that an independent approach to investigating vaccine safety signals could help strengthen public trust.

In a recent invited perspective in the Journal of Infectious Diseases, Salmon and colleagues proposed establishing a National Vaccine Safety Board modeled on the National Transportation Safety Board (NTSB), bringing together existing data and expertise to conduct rapid, independent investigations.

In this MedPage Today video, Salmon explains how such a board would operate and prioritize potential safety concerns, as well as why separating scientific assessments from policy decisions could improve public confidence.

The following is a transcript of his remarks:

I mean, whenever I talk about vaccine safety, and especially when I'm talking about things we could do better, I'm careful to point out that routinely used vaccines in the U.S. are very safe.

Where the idea [for a National Vaccine Safety Board] came from for me was 25 years ago I was at CDC and I was working under Dr. Bob Chen, who ran vaccine safety for CDC, and he brought it up as an analogy. And I really didn't know much about the National Transportation Safety Board. I mean, I knew the name and I'm like, "Oh, those are the people that figured out what happens with plane accidents." And as I learned more about it, I realized how it's a great model for vaccine safety in many, many ways. Most importantly, it's an incredibly trusted organization.

There's a bunch of pieces to this that we outlined in the commentary, and I think that there's ways in which the NTSB model is very useful.

So for one, the party system. So while the NTSB leads the investigation, they work with other parties that have data and expertise, which is really important. So they provide the leadership, they provide the independence.

So in the vaccine-safety world, the analogy would be lots of federal agencies have data, as does industry. And that's great, they should. You want CDC and FDA to be looking at vaccine safety data for their own purposes and their needs. And industry also has data because people make reports to industry and they know their product very well.

But it would be a National Vaccine Safety Board that would lead those efforts. And in doing so, you leverage all the expertise. And they may have their own data just as the NTSB does, but they benefit from everyone's data. But the leadership is independent and it's insulated from other pressures and it makes sure that the best investigation is done and the results are credible.

If you have a vaccine safety signal, you want to investigate it rapidly. So in this case, it's an unusual situation where the speed of spending money is important and they should have the authority to do so.

Are we talking about a vaccine that's given to every child or only used by a much smaller proportion of the population? And is it a vaccine given to vulnerable people like children or pregnant women? How severe is the health event that people are worried about? If we're talking about a low-grade fever, it's probably not going to be a top priority. But is it a serious adverse health outcome? You want to look at scientific concerns because clearly if scientists feel there's a biological mechanism or doctors have concerns, they need to be investigated.

But you also want to look at public concerns because if a lot of people are worried about something, we need science to know. And simply telling people, "Oh, well, we're not worried about that. It's fine," is really kind of insufficient.

So it's a great question. How do you prioritize? I think those are the criteria, and I think it needs public input. It needs input from a broad range of people: the public broadly, parents, pregnant women, doctors, scientists. And it should be a living document because as you're doing science, you should hopefully be able to check things off the list because you've got really good answers. And undoubtedly new things will arise.

So there's a basic principle, and it's well accepted in environmental health and it's well accepted in many domains, which is you need a separation of risk assessment from risk management. And in this case, risk assessment is assessing the safety of vaccines. What is the safety profile of vaccines? That's a scientific question. Now it can be impacted in terms of what you study by the public, but it's fundamentally a scientific question. And risk management is when you consider things like the benefits of vaccines, the cost of vaccines, how hard they would be to implement, or easy.

And there needs to be a separation from risk assessment from risk management so the people that are doing the science around vaccine safety are insulated or protected, but we need that science to be done independently and that will really lead to trust. And we see that with NTSB as a model, as well as other examples.

来源:MedPage Today · medpagetoday.com